Cannabinoid receptors have an impact on gastrointestinal function, but it remains unknown whether mutations may affect tumor susceptibility in patients with esophageal carcinoma. The aim of this study was to determine mutation in the cannabinoid receptor-1 (CNR1) gene and its relation to vascular endothelial growth factor (VEGF) expression as an angiogenic and poor prognostic factor.
Methods
179 esophageal tissue samples from 69 patients (29 with esophageal cancer and 40 controls) were studied. CNR1 gene mutation (1359 G → A in codon 453) was detected with PCR, using the MspI restriction enzyme. VEGF was determined by immunoassay.
Results
Genotyping in control patients’ samples revealed that 24/40 were G/G wild type and 16/40 were G/A; no samples were A/A. Of the 139 tissue samples from the 29 esophageal cancer patients, 15 were G/G homozygous, 85 G/A heterozygous, 11 had an A/A genotype and 28 were without amplification. In the normal tissue adjacent to tumor, some mutations were observed. The overall survival time was reduced in patients with the A/A type in all their 5 samples, in comparison to G/G type (P = 0.04, chi-square: 4.26). VEGF expression was higher in tumor than nontumor areas (P <0.025). VEGF expression was not correlated with survival time.
Conclusions
Our preliminary findings in esophageal tissue showed a high frequency of G → A mutation in the CNR1 gene. No correlation between VEGF expression and gene receptor mutation was found. Patients with mutation in all their samples had a reduced survival time.
PertweeR.G.: Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther, 4: 129–180, 1997.
2.
GadzickiD., Müller-VahlK., StuhrmannM.: A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes, 13: 321–323, 1999.
3.
BlotW.J., McLaughlinJ.K.: The changing epidemiology of esophageal cancer. Sem Oncol, 26: 2–8, 1998.
4.
WuT.T., WatanabeT., HeitmillerR., ZahurakM., ForastiereA.A., HamiltonS.R.: Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol, 153: 287–294, 1998.
5.
WangL.D., ChenH.: Alteration of tumor suppressor gene p53-Rb system and human esophageal carcinogenesis. Shijie Huaren Xiaoluia Zazhi, 9: 367–371, 2002.
BlázquezC., González-Ferial, AlvarezL., HaroA., Llanos CasanovaM., GuzmánM.: Cannabinoids inhibit the vascular endothelial factor pathway in gliomas. Cancer Res, 64: 5617–5623, 2004.
8.
Llanos CasanovaM., BlázquezC., Martínez PalacioJ., VillanuevaC., Fernández-Acereño, HuffmanJ.W., JorcanoJ.L., GuzmanM.: Inhibition of skin tumor growth and angiogénesis in vivo by activation of cannabinoid receptors. J Clin Invest, 111: 43–50, 2003.
9.
GuzmanM., SanchezC., Galve-RoperhI.: Control of cell survival/death decision by cannabinoids. J Mol Med, 78: 613–625, 2001.
10.
MelckD., De PetrocellisL., OrlandoP., BisognoT., LaezzaC., BifulcoM., Di MarzoV.: Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 141: 118–126, 2000.
11.
BifulcoM., LaezzaC., PortellaG., VitaleM., OrlandoP., De PetrocellisL., Di MarzoV.: Control by the endogenous cannabinoid system of ras oncogene-dependent tumor. FASEB J, 15: 2745–2747, 2001.
12.
FerraraN., Davis-SmythT.: The biology of vascular endothelial growth factor. Endocr Rev, 18: 4–25, 1997.
KitadaiY., HarumaK., TokutomiT., TanakaS., SumiiK., CarvalhoM.: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res, 4: 2195–2200, 1998.
15.
MöbiusC., SteinH.J., BeckerI., FeithM., TheisenJ., GaisP., JüttingU., SiewertJ.R.: Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma. World J Surg, 28: 675–6792004.
16.
FerraraN.: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist, 9: 2–10, 2004.
17.
KimuraS., KitadaiY., TanakaS., KuwaiT., HiharaJ., YoshidaK., TogeT., ChamayaK.: Expression of hypoxia-inducible factor (HIF)-1a is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer, 40: 1904–1912, 2004.
18.
BouckN.: Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells, 2: 179–185, 1990.
19.
World Health Organization: International classification of malignant tumours.Springer Verlag, Geneva, 1988.
20.
SobinL.H., WittekindC.H., AkerleyW.: TNM classification of malignant tumours, 6th edition. Wiley-Liss, New York, 2002.
21.
SambrookJ., FritschE., ManniatisT.: Molecular cloning: A laboratory manual.Cold Spring Harbor Laboratory Press, New York, 1989.
22.
VeghI., De la Calle Santiuste, ColinaF., BorL., BermejoC., AragonA., Moran-JimenezM.J., Gómez-CámaraA., Enríquez de SalamancaR., Moreno GonzálezE.: Relationship between biomarker expression and allelic alteration in esophageal carcinoma. J Gastroenterol Hepathol, 22: 2303–2309, 2007.
23.
VeghI., De-la CruzJ., NavarroS., MoralesC., ColinaP., AbadA., De-la-CalleA., Enríquez de SalamancaR., Moreno GonzálezE.: Colorectal cancer relapse: Allelic alterations associated with tumor marker overexpression. Oncology, 65: 146–151, 2003.
24.
BifulcoM., LaezzaC., ValentiM., LigrestiA., PortellaG., Di-MarzoV.: A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J, 18: 1601–1608, 2004.
25.
PeetersA., BeckersS., MertensI., Van HulW., Van GaalL.: The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine, 31: 138–141, 2007.
26.
RussoP., StrazzulloP., CappuccioF.P., TregouetD.A., LauriaF., LoguercioM., BarbaG., VersieroM., SianiA.: Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab, 92: 2382–2386, 2007.
27.
MayerP., HölltV.: Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther, 91: 167–177, 2001.
28.
MayerP., RochlitzH., RauchE., RommelspacherH., HasseH.E., SchmidtS., HölltV.: Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport, 8: 2547–2550, 1997.
29.
HixsonJ.E., AlmasyL., ColeS., BirnbaumS., MitchellB.D., MahaneyM.C., SternM.P., MacCluerJ.W., BlangeroJ., ComuzzieA.G.: Normal variation in leptin levels is associated with polymorphisms in the proopiomelanocortin gene, POMC. J Clin Endocrinol Metab, 84: 3187–3191, 1999.
30.
ChaoH.K., HsiaoKJ, SuT.S.: A silent mutation induces exon skipping in the phenylalanine hydroxylase gene in phenylketonuria. Hum Genet, 108: 14–19, 2001.
31.
MonteraM., PiaggioF., MarcheseC., GismontiU., StellaA., RestaN., VarescoL., GuantiG., MareniC.: A silent mutation in exon 14 of the APC gene is associated with exon skipping in FAP family. J Med Genet, 38: 863–867, 2001.
32.
RenY., CaoB., LawS., XieY., LeeP.Y., CheungL., ChenY., HuangX., ChanH.M., ZhaoP., LukJ., Vande WoudeG., WongJ.: Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res, 11: 6190–6197, 2005.
33.
LinderholmB., LindhB., TavelinB., GrankvistK., HenrikssonR.: p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer, 89: 51–62, 2000.
